Aviado · Research
Longevity Daily
Monday, October 12, 2026
Listen
Today's Brief
Peter Attia's AMA #90 is this week's standout: he has dropped metformin for longevity and is openly rethinking rapamycin—a frank reset from the most data-driven voice in preventive medicine. New research suggests rapamycin may slow the biological changes that precede Alzheimer's symptoms, while a direct AMPK activator extends lifespan across three species, giving the metformin-for-longevity debate fresh context. Our evidence checks take aim at epigenetic clock hype and Neuriva's unsubstantiated claims, and Aviado's analysis of Vitex explains how this botanical works with dopamine-receptor precision.
10 stories2 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Rapamycin May Slow the Pre-Clinical Changes That Lead to Alzheimer's Disease
Research indicates that rapamycin—the transplant drug repurposed by longevity enthusiasts—can slow the biological changes that occur before Alzheimer's clinical symptoms emerge, potentially widening the window for intervention. This pre-clinical phase is where treatment matters most, before neurodegeneration becomes visible on cognitive tests or measurable behavioral decline appears. If validated in human trials, rapamycin's mTOR-inhibiting mechanism could offer a distinct rationale for its use in cognitive protection, separate from its general longevity applications.
Read more →Supplements & Compounds
Neuriva Is One of America's Best-Selling Brain Supplements—But Does It Work?
A clinical review in Pharmacy Times finds that Neuriva's key ingredients lack robust human evidence for cognitive benefit in healthy adults—a significant gap given its popularity and premium price point. The broader supplement market for brain health is booming as the 65+ population grows, but most products have not been tested in the large, well-controlled trials needed to substantiate their marketing claims. If you're spending on a nootropic supplement, this review is a useful baseline for asking harder questions about what's actually in the bottle.
Read more →How Vitex Controls Prolactin With Dopamine-Receptor Precision
Vitex works through a specific, measurable mechanism: it mimics dopamine in the pituitary gland, directly suppressing prolactin—the hormone responsible for cyclical breast pain and irregular periods. Unlike vaguely-marketed "hormone balance" botanicals, Vitex targets a receptor pathway that clinical trials have consistently validated, producing measurable reductions in prolactin levels and improvements in cycle regularity. Expect noticeable results in 8–12 weeks using 20–40 mg of standardized extract daily; look for products specifying casticin and agnuside content, the active compounds behind the dopamine-like effect.
Read the full Aviado analysis →Research & Papers
Epigenetic Age-Reversal Claims Often Collapse Under Multi-Clock Testing
A new study in Aging Cell finds that interventions showing "biological age reversal" on a single epigenetic clock frequently fail to replicate when tested across multiple clocks simultaneously—suggesting many reported anti-aging effects are statistical artifacts rather than genuine rejuvenation signals. The authors propose three validation criteria to separate real aging signals from noise, giving consumers and clinicians a framework to apply skepticism. Before trusting any supplement, protocol, or product claiming to reverse your biological age by a specific number of years, ask whether the finding survived a multi-clock stress test.
Read more →Direct AMPK Activation Extends Lifespan Across Three Species
A targeted compound that directly switches on AMPK—the cell's master energy sensor—extended lifespan across three different species, offering some of the clearest causal evidence yet that this pathway drives aging. Unlike metformin, which activates AMPK indirectly while hitting multiple other biological targets, the new compound isolates AMPK's effect, making the finding harder to explain away as an off-target artifact. This reframes the debate around metformin for longevity: if direct AMPK activation is the key mechanism, more targeted agents may eventually outperform it.
Read more →New Topical Drug Lowers Skin's Biological Age by Two Years in Four Weeks
A new anti-aging drug candidate—applied as a cream—reduced the biological age of participants' skin by approximately two years on average after just four weeks of use, according to results reported by WIRED. The trial is small and the outcome is tissue-specific rather than systemic, but it demonstrates that epigenetic aging markers in a targeted organ can be measurably shifted in a short timeframe. Larger follow-up studies will be needed before this translates into clinical or commercial use—approach with healthy skepticism until they arrive.
Read more →A Longevity Expert Calls Out Four Anti-Aging Claims as Junk Science
A longevity researcher systematically dismantles four widely-shared anti-aging narratives—including Blue Zones and telomere rejuvenation—arguing that the research behind them is methodologically flawed or simply misrepresented. The Blue Zones in particular, long cited as proof that diet and community dramatically extend lifespan, may reflect data artifacts and survivorship bias rather than genuine hotspots of centenarianism. It's a useful corrective for anyone who has built a health strategy around stories that spread through popular media rather than peer-reviewed replication.
Read more →Lifestyle & Nutrition
Peter Attia Updates His Protocol: No More Metformin for Longevity, Growing Doubt on Rapamycin
Peter Attia has publicly walked back two of his most-discussed longevity interventions: he no longer takes metformin, citing concerns that its interference with mitochondrial signaling may blunt exercise adaptations—a tradeoff he no longer considers worth it for healthy adults not managing diabetes. His views on rapamycin have shifted toward "growing uncertainty" despite compelling animal data, because human dosing protocols and long-term risk profiles remain untested. He also revisits his earlier enthusiasm for ketogenic diets and extended fasting, walking through what the evidence actually shows versus what he once believed. For anyone building a longevity protocol around these tools, this AMA is essential listening.
Read more →Industry & Policy
At Harvard's ARDD 2026, GLP-1 Drugs Are Named the First Real Longevity Medicine
The Aging Research and Drug Discovery conference at Harvard brought together frontier AI companies, major pharmaceutical players, and leading longevity scientists in what organizers called an unprecedented cross-industry convergence around aging biology. One headline take: a top venture partner at Qiming declared GLP-1 drugs the "first clinically legitimate longevity medicine," signaling that serious investors are anchoring longevity bets in proven drug classes rather than speculative interventions. For readers tracking where credibility and capital are flowing in longevity science, this conference dispatch offers a useful read on the field's direction.
Read more →Lemme Enters the Longevity Supplement Market With an NMN and Antioxidant Formula
Khloé Kardashian's wellness brand Lemme has launched its first longevity-focused product—Lemme NAD+—combining nicotinamide mononucleotide (NMN) with a patented antioxidant ingredient positioned for skin appearance and anti-aging. The launch signals that NAD+ precursor supplementation has crossed from biohacker subculture into mainstream retail, which will likely accelerate both consumer demand and scrutiny of NMN's actual human evidence base. This is worth watching as a market signal even for consumers who won't buy it.
Read more →